Published in Br J Clin Pharmacol on August 01, 1983
[The sequence of the alpha-amylase inhibitor Hoe-467 A (alpha-amylase inactivator Hoe-467 A) from Streptomyces tendae 4158]. Hoppe Seylers Z Physiol Chem (1981) 1.13
Enzyme inhibitors of microbial origin. Philos Trans R Soc Lond B Biol Sci (1980) 1.06
Bio-availability of three formulations of glibenclamide. S Afr Med J (1989) 1.39
Experience with the intensive care management of organophosphate insecticide poisoning. S Afr Med J (1981) 1.12
Ligation of the patent ductus arteriosus in premature infants: report of 45 cases. J Pediatr Surg (1973) 1.10
[Free-flow electrophoresis. I. Theoretical and experimental investigations of the influence of mechanical and electrokinetic variables on the efficiency of the method]. Hoppe Seylers Z Physiol Chem (1975) 0.96
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol (1995) 0.94
The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J (1990) 0.92
Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.92
South African multicentre trial with Voltaren in osteo-arthritis of the knee. S Afr Med J (1974) 0.90
Caffeine in sport. Urinary excretion of caffeine in healthy volunteers after intake of common caffeine-containing beverages. S Afr Med J (1988) 0.88
The effects of forskolin eye drops on intra-ocular pressure. S Afr Med J (1987) 0.86
Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittelforschung (1989) 0.86
Does cimetidine alter the cardiac response to exercise and propranolol? S Afr Med J (1979) 0.85
A correlative study of serum digoxin levels and electrocardiographic measurements. S Afr Med J (1975) 0.85
Penbutolol and furosemide in a fixed-dose combination-bio-equivalence of two formulations. S Afr Med J (1981) 0.85
Single and divided doses of penbutolol. Clin Pharmacol Ther (1979) 0.85
A multicentre trial of Voltaren in the treatment of rheumatoid Arthritis. S Afr Med J (1974) 0.84
Pharmacokinetic and pharmacodynamic implications of long-term administration of non-steroidal anti-inflammatory agents. Int J Clin Pharmacol Biopharm (1977) 0.84
Pharmacokinetics of ramipril in the elderly. Am J Cardiol (1987) 0.83
Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators. Am J Hypertens (1997) 0.82
Comparative bio-availability of four formulations of furosemide. S Afr Med J (1985) 0.82
The effect of penbutolol on glomerular filtration. S Afr Med J (1981) 0.81
Absolute bioavailability of a new high dose methylprednisolone tablet formulation. Int J Clin Pharmacol Ther (1994) 0.80
No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol (1995) 0.80
The effect of fasting on total serum bilirubin concentrations. Br J Clin Pharmacol (1995) 0.79
Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol (1983) 0.79
Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Hum Toxicol (1983) 0.79
[Effects of smoking and oral contraceptives on plasma and whole blood viscosity. Rheologic studies on normal subjects]. Med Welt (1978) 0.79
Severe mefenamic acid poisoning. A case report. S Afr Med J (1985) 0.78
Ibuprofen bio-availability. A comparison of Brufen and Inza. S Afr Med J (1986) 0.78
Paracetamol overdose: protective effect of concomitantly ingested antimuscarinic drugs and codeine. Hum Toxicol (1983) 0.78
Letter: Ethyl alcohol: contamination of blood specimens. S Afr Med J (1976) 0.78
[Mode of action of pentoxifyllin]. Med Monatsschr (1975) 0.77
Lack of interaction between ramipril and simvastatin. Eur J Clin Pharmacol (1994) 0.77
Effects of tendamistate on postprandial plasma glucose, free fatty acid and triglyceride levels. S Afr Med J (1984) 0.77
Inhibition of starch absorption by tendamistate (an alpha-amylase inactivator). S Afr Med J (1983) 0.76
No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther (1995) 0.76
Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril. Br J Clin Pharmacol (1993) 0.76
Etomidate as anaesthetic induction agent in open-heart surgery. S Afr Med J (1980) 0.76
Availability of phendimetrazine from sustained and non-sustained action formulations. S Afr Med J (1975) 0.76
Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. Arzneimittelforschung (1995) 0.76
Multiple doses of trandolapril do not affect warfarin pharmacodynamics. S Afr Med J (1995) 0.76
Inhibition of starch absorption by alpha-amylase inactivator given with food. Lancet (1983) 0.76
Effect on salivary enzymes of alpha-amylase inhibitor HOE 467. Lancet (1983) 0.76
Digoxin concentrations in serum and saliva: relationship to ECG changes and dosage in healthy volunteers. Br J Clin Pharmacol (1976) 0.75
Salivary digoxin concentrations. Br J Clin Pharmacol (1976) 0.75
[Increase of blood viscosity in rabbits through ethinylestradiol]. Med Welt (1973) 0.75
Decrease in whole blood viscosity in alloxan diabetic rabbits. Acta Diabetol Lat (1976) 0.75
No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther (1996) 0.75
[Investigations on the pharmacokinetics of pentoxifylline in chronic renal failure (authors transl)]. Med Klin (1977) 0.75
Double-blind randomized cross-over trial of nocturnal elixir theophylline supplementation of a twice-daily sustained-release theophylline tablet formulation in asthmatic patients. Chronobiol Int (1993) 0.75
Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet (1997) 0.75
Letter: Diabetic retinopathy. JAMA (1976) 0.75
Considerable cost savings through the analysis of pooled plasma samples in bioequivalence studies that fail to show bioequivalence. Int J Clin Pharmacol Ther Toxicol (1993) 0.75
Pharmacodynamics and tolerability of low doses of tendamistate given with starch. S Afr Med J (1984) 0.75
Biorhythm in the renal excretion of electrolytes and uric acid in healthy subjects. S Afr Med J (1980) 0.75
Erythrocyte deformability in a red cell ageing model. Ric Clin Lab (1978) 0.75
[Blood and plasma viscosity as a basis for clinical hemorheology. Studies on 3 species]. Med Welt (1978) 0.75
Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung (1996) 0.75
[Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency]. Dtsch Med Wochenschr (1973) 0.75
Pharmacokinetics of aprotinin in two patients with chronic renal impairment. Br J Clin Pharmacol (1996) 0.75
[Microrheological studies in healthy subjects. Effect of cigarette smoke and oral contraceptives on erythrocyte flexibility]. Dtsch Med Wochenschr (1978) 0.75
Treatment of uremic bone disease. Action of 5,6-trans-25-hydroxycholecalciferol (a vitamin D-analog) in chronic renal failure. Klin Wochenschr (1973) 0.75
Furosemide chronopharmacology. S Afr Med J (1982) 0.75
The use of renal enzymes as early indication of renal toxicity after multiple-dose administration of aspirin. S Afr Med J (1983) 0.75
[The effect of pentoxifyllin on the surface tension of the human blood]. Med Welt (1975) 0.75
Red blood cell aging as a model to influence pharmacologically the red cell filterability. Res Exp Med (Berl) (1981) 0.75
Theophylline dose-concentration relationship of a 12-hourly Nuelin SA regimen supplemented with nocturnal nuelin liquid in healthy volunteers. Chronobiol Int (1993) 0.75
Potassium balance in piretanide and digoxin treatment. Clin Pharmacol Ther (1982) 0.75
Starch blockers. Lancet (1983) 0.75
Pharmacodynamics and urine pharmacokinetics of three doses of piretanide. Eur J Clin Pharmacol (1983) 0.75
Pharmacokinetics of 5,6-trans-25-hydroxycholecalciferol, a synthetic analogue of vitamin D3, in man. Eur J Clin Pharmacol (1975) 0.75
Microrheological effects of the vasoactive compound 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (pentoxifylline, BL 191). Vasa (1977) 0.75
[The effect of pentoxifyllin on the cyclic AMP-system in thrombocytes]. Med Welt (1975) 0.75
The metabolism and organ distribution of 5,6-trans-25-hydroxycholecalciferol, an analog of vitamin D-3 in vitamin D-deficient rats. Res Exp Med (Berl) (1975) 0.75
Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives. Int J Clin Pharmacol Ther Toxicol (1993) 0.75
Steady-state pharmacokinetics of phentermine extended-release capsules. Int J Clin Pharmacol Ther Toxicol (1993) 0.75
[Treatment of renal osteopathy with 5,6-trans-25-hydroxycholecalciferol (author's transl)]. Dtsch Med Wochenschr (1979) 0.75
[Hemorheologic examinations of smokers. A review]. Med Welt (1981) 0.75
[Blood viscosity and diabetes mellitus]. Med Monatsschr (1973) 0.75
Relative bioavailability of four controlled-release nifedipine products. Biopharm Drug Dispos (1994) 0.75
Pantothenic acid and vitamin B6 in beef. J Am Diet Assoc (1969) 0.75